A new era for radiolabeled antibodies in cancer? (Q33745192)

29 July 2017

1 reference

title

A new era for radiolabeled antibodies in cancer? (English)

1 reference

29 July 2017

DeNardo SJ

1

1 reference

29 July 2017

Kroger LA

series ordinal

2

1 reference

29 July 2017

DeNardo GL

series ordinal

3

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Current Opinion in Immunology

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

563-569

1 reference

Trials and tribulations: oncological antibody imaging comes to the fore

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

A revolution in the treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

The development of monoclonal antibodies for the therapy of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Pretargeted peptide imaging and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

Pretargeting with the affinity enhancement system for radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900017-5

7 January 2021

10.1016/S0952-7915(99)00017-5

Identifiers

DOI

1 reference

29 July 2017

1 reference